Aadi Bioscience, Inc. (AADI)
$
2.05
-0.05 (-2.44%)
Key metrics
Financial statements
Free cash flow per share
-1.4136
Market cap
126.8 Million
Price to sales ratio
8.8136
Debt to equity
0
Current ratio
16.7566
Income quality
9.1727
Average inventory
0
ROE
-0.1035
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of precision therapies targeting genetically defined cancers associated with mTOR pathway gene alterations. The company’s lead drug candidate, FYARRO, is a formulation of sirolimus bound to albumin that is currently under evaluation for its efficacy in cancers known to exhibit mTOR pathway activation. This includes tumor-agnostic indications aimed at specific genomic alterations that activate the mTOR pathway. The weighted average number of diluted shares outstanding is 27,029,942.00 reflecting potential dilution effects on existing shareholders. Furthermore, the operating expenses amount to $90,417,000.00 encompassing various operational costs incurred by the company during its research and development activities. As part of its financial obligations, the company incurred an income tax expense of $0.00 indicating its tax liabilities. The gross profit ratio is 0.88 which reflects the efficiency of the company's production and sales operations, while the income before tax ratio stands at -2.45 illustrating the firm’s pre-tax margin that indicates operational profitability prior to taxation. As of the current market analysis, the stock is affordable at $2.05 making it suitable for budget-conscious investors who are looking to participate in the potential upside of the company’s innovative therapies. The stock, however, has a low average trading volume of 200,709.00 indicating lower market activity, which may affect liquidity for some investors. With a market capitalization of $94,891,630.00 the company is classified as a small-cap player, highlighting its growth potential in a competitive industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, particularly in the realm of precision oncology. Moreover, it belongs to the Healthcare sector, which is driving innovation and growth as biotechnology and personalized medicine continue to advance, reflecting the ongoing evolution in cancer treatment methodologies and therapeutic options available to patients.
What is Aadi Bioscience, Inc. (AADI)'s stock forecast?
Analysts predict Aadi Bioscience, Inc. stock to fluctuate between $1.21 (low) and $3.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aadi Bioscience, Inc.'s market capitalization?
As of 2025-03-18, Aadi Bioscience, Inc.'s market cap is $94,891,630, based on 46,288,600 outstanding shares.
How does Aadi Bioscience, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aadi Bioscience, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aadi Bioscience, Inc. (AADI) stock?
To buy Aadi Bioscience, Inc. (AADI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AADI. Place an order (Market, Limit, etc.).
What is the best time to invest in Aadi Bioscience, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Aadi Bioscience, Inc. stock ever split?
Aadi Bioscience, Inc.'s last stock split was 1:15 on 2021-08-27.
How did Aadi Bioscience, Inc. perform in the last earnings report?
Revenue: $25,983,000 | EPS: -$2.36 | Growth: -3.28%.
Where can I find Aadi Bioscience, Inc.'s investor relations reports?
Visit https://aadibio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aadi Bioscience, Inc.?
You can explore historical data from here
What is the all-time high and low for Aadi Bioscience, Inc. stock?
All-time high: $32.99 (2021-09-23) | All-time low: $1.21 (2024-08-08).
What are the key trends affecting Aadi Bioscience, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
2 days ago
Profitability This table compares Aadi Bioscience and Nabriva Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Nabriva Therapeutics -148.11% -365.53% -135.81% Institutional and Insider Ownership 52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics
defenseworld.net
8 days ago
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Aadi Bioscience (NASDAQ: AADI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings. Volatility and Risk Actinium Pharmaceuticals has a
defenseworld.net
a month ago
Risk and Volatility Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Valuation and Earnings This table compares Eagle Pharmaceuticals and Aadi Bioscience"s
prnewswire.com
10 months ago
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision.
prnewswire.com
a year ago
MORRISTOWN, N.J. , March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025.
zacks.com
a year ago
Aadi Bioscience (AADI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
prnewswire.com
a year ago
MORRISTOWN, N.J. , March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement.
prnewswire.com
a year ago
MORRISTOWN, N.J. , March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025.
zacks.com
a year ago
Aadi Bioscience (AADI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
prnewswire.com
a year ago
MORRISTOWN, N.J. , Feb. 24, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA.
See all news
